organ transplantation – CRI Report https://www.cri-report.com market research vender! Thu, 02 Dec 2021 07:18:55 +0000 en-US hourly 1 https://www.cri-report.com/wp-content/uploads/2021/01/cropped-shcrilogo-c.jpg organ transplantation – CRI Report https://www.cri-report.com 32 32 Investigation Report on China’s Mycophenolate Mofetil Market 2021-2025 https://www.cri-report.com/investigation-report-on-chinas-mycophenolate-mofetil-market-2021-2025/ Mon, 19 Jul 2021 02:43:40 +0000 https://www.cri-report.com/?post_type=product&p=13242 In 2020, due to the impact of the Covid-19 epidemic on the overall medical diagnosis and treatment services, the growth rate of sales has decreased. However, the sales still reached CNY 921 million, with a CAGR of 6.54% from 2016 to 2020.

The post Investigation Report on China’s Mycophenolate Mofetil Market 2021-2025 first appeared on CRI Report.

]]> Mycophenolate mofetil is a powerful inhibitor of lymphocyte proliferation and has been used to prevent acute rejection of allografts since the early 1990s. Mycophenolate mofetil is also widely used as a glucocorticoid reducing agent to treat patients with various rheumatic diseases, including systemic lupus erythematosus (SLE), systemic sclerosis (SSc), inflammation Myopathy and some systemic vasculitis.

Mycophenolate mofetil was developed by Roche Pharmaceuticals Co., Ltd., and the trade name of Mycophenolate mofetil from Roche is CELLCEPT. CELLCEPT was first approved by the NMPA for listing in China in 2004, and then generic drugs from local Chinese companies have also been listed successively. By 2020, there are many manufacturers in China’s mycophenolate mofetil market, among which Shanghai Roche Pharmaceuticals Co., Ltd. has the highest sales market share.

According to CRI’s research market, the sales of mycophenolate mofetil in the Chinese market have increased year by year from 2016 to 2020. In 2020, due to the impact of the Covid-19 epidemic on the overall medical diagnosis and treatment services, the growth rate of sales has decreased. However, the sales still reached CNY 921 million, with a CAGR of 6.54% from 2016 to 2020.

CRI expects that with the effective alleviation of the Covid-19 epidemic, the sales of mycophenolate mofetil in the Chinese market will have a restorative growth from 2021 to 2025. At the same time, compared with similar drugs, mycophenolate mofetil is safer and more effective. Based on these advantages, the sales volume and sales of mycophenolate mofetil in the Chinese market will continue to grow from 2021 to 2025.

Topics Covered:

-The impact of COVID-19 on China’s Mycophenolate Mofetil market

– Sales value of China’s Mycophenolate Mofetil 2016-2020

– Competitive landscape of China’s Mycophenolate Mofetil market

– Prices of Mycophenolate Mofetil in China

– Prices of Mycophenolate Mofetil in China by regions and manufacturers

– Analysis on factors affecting the development of China’s Mycophenolate Mofetil market

– Prospect of China’s Mycophenolate Mofetil market from 2021 to 2025

The post Investigation Report on China’s Mycophenolate Mofetil Market 2021-2025 first appeared on CRI Report.

]]> Research Report of Organ Transplantation in China 2020-2024 https://www.cri-report.com/research-report-of-organ-transplantation-in-china-2020-2024/ Thu, 23 Jan 2020 05:36:21 +0000 https://www.cri-report.com/product/import-placeholder-for-2001411/ According to CRI’s market research, transplantation has become an important way to save the lives of patients with critical diseases such as liver failure and kidney failure. Human organ transplantation in China began to be performed in the 1960s and grew more mature in 1990s. The number of organ transplants kept increasing and the survival rates of patients and grafts rose significantly. The annual number of organ transplants in China increased from 5,000 many years ago to more than 20,000 in 2018. Able to transplant livers, kidneys, hearts, lungs, small…

The post Research Report of Organ Transplantation in China 2020-2024 first appeared on CRI Report.

]]> According to CRI’s market research, transplantation has become an important way to save the lives of patients with critical diseases such as liver failure and kidney failure. Human organ transplantation in China began to be performed in the 1960s and grew more mature in 1990s. The number of organ transplants kept increasing and the survival rates of patients and grafts rose significantly. The annual number of organ transplants in China increased from 5,000 many years ago to more than 20,000 in 2018. Able to transplant livers, kidneys, hearts, lungs, small intestines and perform simultaneous pancreas-kidney transplants and multiple-organ transplants, China became the country second only to the United States in terms of the number of organ transplants, and is expected to become the country with the largest number of organ transplants in 2020. The increasing number of organ transplants in China greatly expands the market of immunosuppressive drugs that organ transplant recipients need to take for life.
With wider clinical application of new immunosuppressant, the market size of immunosuppressants in China exceeded CNY 15 billion in 2018.
Since the Chinese government announced the suspension of using the organs of condemned prisoners for organ transplantation in 2015, organ donation became the only legal source of supply. However, affected by traditional mind, most Chinese people are reluctant to donate their organs. The undersupply of transplant organs cannot be addressed in the short term, which creates a breeding ground for the black-market trade in organs.
According to CRI’s market research, although facing challenges, the annual number of organ transplantation is estimated to be more than 40 thousand according to CRI, and the market of immunosuppressants is expected to be over CNY 30 billion by 2024.

Topics covered:
Introduction
Development Environment
Development Status in China
Relevant Market
Prospect of China’s Organ Transplant Industry

The post Research Report of Organ Transplantation in China 2020-2024 first appeared on CRI Report.

]]>